Skip to content

house · Committee report

H. Rept. 118-75

PREVENTING THE FINANCING OF ILLEGAL SYNTHETIC DRUGS ACT

2023-05-22

Committees

Associated legislation

Text

Purpose and Summary

Introduced on February 17, 2023, by Representative Monica De La Cruz, H.R. 1076, the Preventing the Financing of Illegal Synthetic Drugs Act, instructs the Comptroller General of the United States to carry out a study on illicit financing in connection with the trafficking of synthetic drugs and related illicit finance. Without financing, a business cannot operate. The study will provide policymakers with better information on how traffickers operate and facilitate illicit activity to draft effective legislation.

Background and Need for Legislation

According to the Center for Disease Control, over 107,000 people in the United States died from drug overdoses or drug poisons in 2022.\1\ Sixty-seven percent of those deaths involved synthetic opioids like fentanyl. Financing is essential to support and sustain the logistics needed to carry out large and small-scale trafficking operations. A detailed study examining the business model of synthetic trafficking, the ways in which the business model overlaps with human trafficking, and the use of online illicit drug markets and financial methods used to carry out illicit activity will allow policymakers to better prioritize U.S. government activities to combat the illicit finance related to the trafficking of synthetic drugs. --------------------------------------------------------------------------- \1\https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/ 202205.htm. --------------------------------------------------------------------------- HEARING The Committee on Financial Services held a hearing examining matters relating to H.R. 1076 on February 7, 2023.

Committee Consideration

The Committee on Financial Services met in open session on February 28, 2023, and ordered H.R. 1076 to be reported favorably to the House as amended by voice vote, a quorum being present. Before the question to report was called, the Committee adopted an amendment in the nature of a substitute offered by Ms. De La Cruz by voice vote.

Committee Votes

Clause 2(b) of rule XIII of the Rules of the House of Representatives requires the Committee to list the record votes on the order to report legislation and amendments thereto. H.R. 1076 was reported favorably to the House as amended by voice vote, a quorum being present. COMMITTEE OVERSIGHT FINDINGS Pursuant to clause 3(c) of rule XIII of the Rules of the House of Representatives, the findings and recommendations of the Committee based on oversight activities under clause 2(b)(1) of rule X of the Rules of the House of Representatives, are incorporated in the descriptive portions of this report. PERFORMANCE GOALS AND OBJECTIVES Pursuant to clause 3(c)(4) of rule XIII of the Rules of the House of Representatives, the goal of H.R. 1076 is to provide lawmakers with better information on how traffickers operate and facilitate illicit activity to draft effective legislation through a study, conducted by the Comptroller General of the United States, on illicit financing in connection with the trafficking of synthetic drugs and related illicit finance. NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY, AND TAX EXPENDITURES In compliance with clause 3(c)(2) of rule XIII of the Rules of the House of Representatives, the Committee adopts as its own the estimate of new budget authority, entitlement authority, or tax expenditures or revenues contained in the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1973. CONGRESSIONAL BUDGET OFFICE ESTIMATES Pursuant to clause 3(c)(3) of rule XIII of the Rules of the House of Representatives, the following is the cost estimate provided by the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] H.R. 1076 would require the Government Accountability Office (GAO) to study the illicit financing of synthetic-drug trafficking and the federal government's efforts to combat those activities. The bill would require the GAO to report its findings to the Congress within one year of enactment. Based on the cost to produce similar reports, CBO estimates that implementing H.R. 1076 would cost less than $500,000 over the 2023-2028 period; any such spending would be subject to the availability of appropriated funds. The CBO staff contact for this estimate is Jeremy Crimm. The estimate was reviewed by Chad Chirico, Deputy Director of Budget Analysis. Phillip L. Swagel, Director, Congressional Budget Office. FEDERAL MANDATES STATEMENT This information is provided in accordance with section 423 of the Unfunded Mandates Reform Act of 1995. The Committee has determined that the bill does not contain Federal mandates on the private sector. The Committee has determined that the bill does not impose a Federal intergovernmental mandate on State, local, or tribal governments. ADVISORY COMMITTEE STATEMENT No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. APPLICABILITY TO LEGISLATIVE BRANCH The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of the section 102(b)(3) of the Congressional Accountability Act. EARMARK IDENTIFICATION With respect to clause 9 of rule XIII of the Rules of the House of Representatives, the Committee has carefully reviewed the provisions of the bill and states that the provisions of the bill do not contain any congressional earmarks, limited tax benefits, or limited tariff benefits within the meaning of the rule. DUPLICATION OF FEDERAL PROGRAMS In compliance with clause 3(c)(5) of rule XIII of the Rules of the House of Representatives, the Committee states that no provision of the bill establishes or reauthorizes: (1) a program of the Federal Government known to be duplicative of another Federal program; (2) a program included in any report form the Government Accountability Office to Congress pursuant to section 21 of Public Law 111-139; or (3) a program related to a program identified in the most recent Catalog of Federal Domestic Assistance, published pursuant to the Federal Program Information Act (Pub. L. No. 85-220, as amended by Pub. L. No. 98-169). SECTION-BY-SECTION ANALYSIS OF THE LEGISLATION Sec. 1: Short title This Act may be cited as the ``Preventing the Financing of Illegal Synthetic Drugs Act''. Sec. 2: Findings This section sets out a series of findings describing the financing of, trafficking in, and the pervasiveness use of synthetic drugs, including fentanyl. Sec. 3: GAO study on synthetic drugs trafficking This section directs the Comptroller General of the United States to carry out a study on illicit financing in connection with the trafficking of synthetic drugs, including fentanyl. CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED H.R. 1076 does not repeal or amend any section of a statute. Therefore, the Office of Legislative Counsel did not prepare the report contemplated by clause 3(e)(1)(B) of rule XIII of the House of Representatives. [all]

Source: https://api.congress.gov/v3/committee-report/118/hrpt/75